Riskpilot← Back to searchSign inGet full accessANASTOMOSIS AS
ASActiveOrg 999217087Consul Sigval Bergesens Vei 112, Leilighet 0302, 4016 StavangerEngineering activities and related technical consultancy · NACE 7112Est. 20120 employees
Revenue 2024
NOK 0
EBITDA margin
—
-24% vs 2023
Equity ratio
-14.8%
Financial strength
Net profit 2024
NOK -106K
-24% vs 2023
| Revenue | NOK 0 | — |
| EBITDA | NOK -106K | -24% |
| Net profit | NOK -106K | -24% |
| Total assets | NOK 900K | +10% |
| Equity | NOK -133K | -397% |
| Employees | 0 | — |
Legal name
ANASTOMOSIS AS
Org number
999217087
Legal form
Aksjeselskap
NACE code
7112 · Engineering activities and related technical consultancy
Founded
3. desember 2012
Share capital
NOK 370 000
Employees
0
VAT registered
No
Audit selected
No
Last report
2024-12-31
Financial year
January – December
Signatory rights
Styrets leder og ett styremedlem i fellesskap.
Company purpose
Utvikler medisinsk teknisk utstyr.
Address
Consul Sigval Bergesens Vei 112, Leilighet 0302, 4016 Stavanger
Risika for professionals
Risika provides regulated workflow tools for finance, procurement and compliance teams that need monitoring, alerts and an API.
| Item | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|
| Revenue | 0 | 0 | 0 | 0 | 0 |
| Staff expenses | −0 | −0 | −0 | −0 | −0 |
| EBITDA | −143 | −133 | −75 | −86 | −106 |
| Depreciation & amort. | −0 | −0 | −0 | −0 | −0 |
| EBIT | −143 | −133 | −75 | −86 | −106 |
| Net financials | −6 | 0 | 0 | −0 | 0 |
| Profit before tax | −149 | −133 | −75 | −86 | −106 |
| Tax | −0 | −0 | −0 | −0 | −0 |
| Net profit | −149 | −133 | −75 | −86 | −106 |
| Item | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|
| Total assets | 815 | 823 | 846 | 816 | 900 |
| Equity | 267 | 134 | 59 | −27 | −133 |
| Long-term debt | 205 | 355 | 462 | 517 | 708 |
| Short-term debt | 343 | 334 | 325 | 325 | 325 |
| Total debt | 548 | 689 | 787 | 842 | 1 033 |
EBITDA margin
-10645900.0%
This company
15.8%
Market median
-67379214% vs market
20202024
Equity ratio
-14.8%
This company
38.2%
Market median
-139% vs market
20202024
Return on equity
-10645900.0%
This company
18.4%
Market median
-57858252% vs market
20202024
Net profit margin
-10645900.0%
This company
8.1%
Market median
-131430964% vs market
20202024
Asset turnover
0.00×
This company
1.12×
Market median
-100% vs market
20202024
Debt / equity
7.76×
This company
0.62×
Market median
-1152% vs market
20202024
- Annual report 2024Filed via Brønnøysundsregistrene · Period 2024-01-01 – 2024-12-31
- Annual report 2023Filed via Brønnøysundsregistrene · Period 2023-01-01 – 2023-12-31
- Annual report 2022Filed via Brønnøysundsregistrene · Period 2022-01-01 – 2022-12-31
- Annual report 2021Filed via Brønnøysundsregistrene · Period 2021-01-01 – 2021-12-31
- Annual report 2020Filed via Brønnøysundsregistrene · Period 2020-01-01 – 2020-12-31
| Name | Role | Member since |
|---|---|---|
| Current (1) | ||
TE Chief Executive Officer | Chief Executive Officer | 2014 |
| Name | Role | Member since |
|---|---|---|
| Current (2) | ||
| Chairman | 2021 | |
| Board of Directors | 2021 | |
| Former (1) | ||
| Board of Directors | 2021 – 2023 | |
| Shareholder | Type | Ownership | Votes | Since |
|---|---|---|---|---|
| Company | 40.66% | 40.66% | 2022 | |
| Company | 24.66% | 24.66% | 2022 | |
| Individual | 3% | 3% | 2022 |
Beneficial ownership (UBO) data access is restricted in Denmark as of September 2025 per the EU 6th AML Directive. Learn more.
Norce Norwegian Research Centre As
ANASTOMOSIS AS Board members of ANASTOMOSIS AS also hold positions in 0 other companies.
| Person | Role here | Other companies |
|---|---|---|
| Terje Engeseth | Chief Executive Officer | 0 companies |
| Gunnar Kleppe | Chairman | 0 companies |
| Sumit Kumar Roy | Board of Directors | 0 companies |
| Arild Willy Kristensen | Board of Directors | 0 companies |